trending Market Intelligence /marketintelligence/en/news-insights/trending/blUy0Fi3M16AM7A5Z9D5CA2 content esgSubNav
In This List

French biopharma Advicenne plans secondary listing on Euronext Brussels

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


French biopharma Advicenne plans secondary listing on Euronext Brussels

France's Advicenne SA, a biopharmaceutical company developing therapies for orphan diseases, is planning a secondary listing on the Euronext Brussels stock exchange.

The company's ordinary shares are currently listed on the Euronext Paris stock exchange and would be cross listed on the Euronext Brussels if the proposed listing is approved. Euronext Paris will remain as the company's primary listing venue.

The cross listing will increase the visibility of Advicenne's shares in Belgium and beyond, the company said in a news release. Advicenne is conducting a phase 2/3 study of its lead product ADV7103 in Belgium for treating cystinuria, a rare kidney disease.

The cross listing would have no impact on Advicenne's current shareholders.